Therapeutic Equivalence and mg:mg Switch Ability of a Generic Cyclosporine Microemulsion Formulation (Sigmasporin Microral) in Stable Renal Transplant Patients Maintained on Sandimmun Neoral

Transplantation Proceedings

Volumn 40, Issue 7, 2008, Pages 2252-2257

  Al Wakeel, J S ^a   Shaheen, F A M ^b   Mathew, M C ^c   Abouzeinab, H M ^d   Al Alfi, A ^e   Tarif, N M ^a   Al Mousawi, M S A ^f   Mahmoud, T S ^f   Alorrayed, A S ^g   Fagir, E A ^h   Dham, R S ⁱ   Shaker, D S ⁱ  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b Saudi Center for Organ Transplantation   (Saudi Arabia)

^c Al Qassimi Hospital   (United Arab Emirates)

^d Hammoud Academic Medical Center   (Lebanon)

^e KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^f IBN SINA HOSPITAL   (Kuwait)

^g Salmaniya Hospital   (Bahrain)

^h IBHO and SBG Hospitals   (United Arab Emirates)

ⁱ Dubai Research Center   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SIGMASPORIN MICRORAL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY GRAFT; MALE; PRIORITY JOURNAL;

ADULT; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUGS, GENERIC; EMULSIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 51249092825     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.06.043     Document Type: Article

References (42)

1. Halloran P.F., Helms L.M., Kung L., et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 68 (1999) 1356
2. Neumayer H.H., Faerber L., Haller P., et al. Substitution of conventional cyclosporine with a new microemulsion formulation in renal transplant patients: results after 1 year. Nephrol Dial Transplant 11 11 (1996) 165
3. Kovarik J.M., Mueller E.A., van Bree J.B., et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-multicenter investigations in kidney transplant patients. Transplantation 58 (1994) 658
4. Rang H.P., Dale M.M., Ritter J.M., et al. Pharmacology (1995), Churchill Livingstone, New York 59
5. Benet L.Z., and Goyan J.E. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 15 (1995) 433
6. Code of Federal regulations (1997), US Government Printing Office, Washington, DC 21CFR320.33(c)
7. Barr W.H. Scientific and professional concerns regarding product interchange and subsequent monitoring of cyclosporine and other critical dose drugs. Transplant Proc 31 (1999) 1645
8. Sheiner L.B. Stat Med 8 (1992) 512
9. Hauck W.W., and Anderson S. Effect of changing the bioequivalence range from (0.80, 120) to (0.80, 1.25) on the power and sample size. Int J Clin Pharmacol Thera Toxicol 30 (1992) 575
10. Johnston A., Keown P.A., and Holt D.W. Simple bioequivalence criteria: are they relevant to critical dose drugs?. Experience gained from cyclosporine. Ther Drug Monit 19 (1997) 375
11. Pidgen A. Bioequivalence and generic prescribing: an industrial view. J Pharm Pharmacol 48 (1996) 11
12. Meredith P.A. Generic drugs. Therapeutic equivalence. Drug Saf 15 (1996) 233
13. Colaizzi J.L., and Lowenthal D.T. Critical therapeutic categories: a contraindication to generic subsitute?. Clinical Therapy 8 (1986) 370
14. Olyaei A.J., deMattos A.M., and Bennet W.M. Switching between cyclosporine formulations. What are the risks?. Drug Saf 16 (1997) 366
15. Nightingale S.L. From the Food and Drug Administration. JAMA 279 (1998) 645
16. Gannon P.M. Documentation of drug interchange in the medical record. Hosp Pharm 26 (1991) 14
17. Mueller E.A., Kovarik J.M., Van Bree J.B., et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 11 (1994) 301
18. Kovarik J.M., Mueller E.A., van Bree J.B., et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-a multicenter investigation in kidney transplant patients. Transplantation 58 (1994) 658
19. Kahan B.D., Welsh M., and Rutzky L.P. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit 17 (1995) 621
20. Expert Advisory Committee on Bioavailability. Report C: Report on bioavailability of oral dosage formulations, not in modified release form, of drugs used for systemic effects, having complicated or variable pharmacokinetics (1992). www.hc-sc.gc.ca
21. Degiorgio V., Piazza R., and Oliani C. Characterization of microemulsion: a dynamic light scattering investigation of cyclosporine-A preparations. Acta Technologiae et Legis Medicamenti 9 (1998) 133
22. Tanasescu C., Serbanescu A., Spadaro A., et al. Comparison of two microemulsion of cyclosporine A in healthy volunteers. Eur Rev Med Pharmacol Sci 3 (1999) 5
23. Single dose, open label, two way treatment, two way crossover comparative bioavailability study of Sigmasporin Microral 100mg soft gelatin capsule and Sandimmun Neoral 100mg soft gelatin capsule in healthy human subjects under fasting and fed conditions. Data on files. Conducted at Anapharm and Allied Clinical Research, Canada.
24. Naji M., Najib N.I., Aymen A., et al. Comparison of two cyclosporine formulations in healthy Middle Eastern volunteers: bioequivalence of the new Sigmasporin Microral and Sandimmun Neoral. Eur J Pharm Biopharm 55 (2003) 67
25. Sineschu I., Vasconcellos L.H., Foschi D., et al. New cyclosporine microemulsion randomized bioequivalence steady-state study in renal transplanted patients. Eur Rev Med Pharmacol Sci 3 (1999) 11
26. Olej B., Lugon J.R., et al. Immunosuppressive activity of cyclosporine A formulations in mononuclear cells. Brazilian J Nephrol 24 suppl IA (2002) 9
27. Elisa G., Mendes F., and Emmanuel A. A comparison between the experimental nephrotoxicity of two cyclosporine A microemulsion formulations. Brazilian J Nephrol 24 suppl IA (2002) 31
28. de Mello V.R., Guersoni A.C., et al. Cyclosporine in treatment of steroid resistant and steroid dependent idiopathic nephritic syndrome. Brazilian J Nephrol 24 suppl IA (2002) 19
29. Manrique R., Magalhaes H.M., Dinhuysen J., et al. Clinical pharmacokinetic comparison between microemulsion formulations of cyclosporine A in heart transplant patients. Brazilian J of Nephrol 24 suppl IA (2002) 45
30. Assbu M.S., Magalhaes M.V., Cruz C., et al. Conversion of Sandimmun Neoral to Sigmasporin Microral in stable renal transplant patients. Brazilian J of Nephrol 23 suppl 2 (2001) 8
31. Palma-Aguirre A.J. Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. J Clin Pharmacol 37 (1997) 630
32. Einecke G., Mai I., Fritsche L., et al. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant 19 (2004) 215
33. Perlik F., Masri M., Rost M., et al. Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149 (2005) 309
34. Pollard S., Nashan B., Johnston A., et al. Pharmacokinetic and clinical review of the potential clinical impact of using different formulation of cyclosporine A. Clin Ther 25 (2003) 1654
35. Nankivell B.J., Hibbins M., and Chapman J.R. Diagnostic utility of whole blood cyclosporine measurement in renal transplant using triple therapy. Transplantation 58 (1994) 989
36. Oellerich M., Armstrong V.W., Kahan B., et al. Lake Louise Consensus Conference on cyclosporine monitoring in organ transplantation: report of consensus panel. Ther Drug Monit 17 (1995) 642
37. 2 monitoring in the long term management of renal transplant recipient. Transplantation 75 (2003) 2086
38. Johnston A., David O.J., and Cooney G.F. Pharmacokinetic validation of Neoral absorption profiling. Transplant Proc 32 (2000) 53S
39. Mahalati K., Belitsky P., Sketris I., et al. Neoral monitored by simplified spares sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplant. Transplantation 68 (1999) 55
40. max) correlate with freedom from liver graft rejection: results of a prospective randomized comparison of Neoral and Sandimmun for liver transplant (NOF-8). Transplantation 67 (1999) 1133
41. Cantarovich M., Besner J.G., Barkun J.S., et al. Two hour cyclosporine level determination is appropriate tool to monitor Neoral therapy. Clin Transplant 12 (1998) 243
42. Eineecke G., Mai I., Diekmann F., et al. Cyclosporine absorption profiling and therapeutic drug monitoring using C2 blood levels in stable renal allograft recipients. Transplant Proc 34 (2002) 1738